We start our third quarter having acquired enabling new technology that expands our oral drug delivery capabilities, along with a significant capital infusion. We are pleased to share our post-acquisition investor presentation below, integrating the technology acquired from Chemistry Holdings in our product pipeline. Our primary focus will be on the pharmaceutical and nutraceutical cannabinoid programs, in addition to the clinical development of CUREfilm® Blue, our oral soluble film formulation of Sildenafil.
~ Rob Davidson, CEO, CURE Pharmaceutical
Acquisition of Chemistry Holdings closes
In May, we closed on our acquisition of Chemistry Holdings Inc., a formulation technology company that is developing innovative delivery systems for a variety of industries. The acquisition was an all-stock transaction using common stock.
In connection with the signing and closing of this acquisition, CURE received a total of $10M in cash. This acquisition brings capital as well as novel intellectual property and scientific expertise to CURE’s capabilities, helping us deliver on our promise to transform patient’s lives with breakthrough medical treatments. This transaction along with capital raised from private placement of shares since April 1, 2019 at $3.34 per share strengthens our balance sheet and bolsters our position as a pioneer and leader in the drug delivery market.
Our platform expansion
This acquisition expands our platform of oral dosage forms beyond dissolving films and allows the company to pursue multiple encapsulations methods for improving the solubility of active ingredients.
The acquired technology includes a novel chewable delivery system, nanoemulsions, microemulsions, microcapsules and taste masking solutions. These technologies complement and expand our CUREfilm ® platform to enable the delivery of a wider range of active ingredients at higher doses. The combined technologies create a versatile platform for both immediate and controlled-release drug delivery.
You can read more about these new technologies by downloading our post-acquisition investor presentation below!
CBD with Canopy Growth
We are collaborating with Canopy Growth Corporation to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using our patented CUREfilm® technology for global distribution. This CUREfilm® license gives Canopy a dosage form that is ideal for administering cannabinoids.
More details – https://curepharmaceutical.com/multimedia/press-releases/cure-pharmaceutical-and-canopy-growth-to-produce-cbd-oral-thin-films?utm_source=CURE+Pharmaceutical+Master+Email+List&utm_campaign=019c846a54-Q2_UPDATE_8_7_2019_COPY_01&utm_medium=email&utm_term=0_bf02d4790f-019c846a54-73172501
Intellectual Property – Patent Portfolio Update
We continue to expand our intellectual property portfolio with three new patents since May. One patent, issued mid-May, covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). This patent secures a critical advantage – the ability to deliver high loads of cannabinoid active molecules with an oral thin film for optimal efficacy and dosing frequency.
Another patent expands on CURE’s proprietary drug delivery system, CUREfilm® to include bi-phasic release of natural active ingredients with the potential for increasing the overall drug load while retaining a rapid dissolution profile. Bi-phasic release provides an initial burst of drug release followed by a constant rate of distribution over a defined period of time for optimal therapeutic benefit.
Our latest patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes. This enables CURE to differentiate its OTF product for specific drug opportunities such as cannabidiol and sildenafil oral soluble films.
Welcome to our new members of the Board
Today, we are pleased to announce new members of our Board of Directors. Lauren Chung, Ph.D. and Anya Goldin bring years of experience and expertise to our board, along with gender diversity, which we believe will further enhance decision making and strengthen our leadership team. In addition, we also welcome the founder of Chemistry Holdings, Joshua Held, who joined our Board in May.
OUR BOARD OF DIRECTORS- https://curepharmaceutical.com/about/board-of-directors?utm_source=CURE+Pharmaceutical+Master+Email+List&utm_campaign=019c846a54-Q2_UPDATE_8_7_2019_COPY_01&utm_medium=email&utm_term=0_bf02d4790f-019c846a54-73172501
CURE in the Media
Rob on TD Ameritrade
CURE’s CEO, Rob Davidson, appeared on The Watch List to discuss our work and innovation in drug delivery technologies.
CURE named a top player in global oral thin film
According to the latest report published in June 2019 by Market Research Future Reports, the Global Oral Thin Film Drugs Market is all set to expand at a CAGR of 10.50% from 2018 to 2023, spurred by an expanding geriatric population and the need for advanced drug delivery methods. CURE was named by the report as one of the top five global players in the arena.
READ MORE- https://marketersmedia.com/oral-thin-film-drugs-market-has-spurred-tremendously-at-1050-cagr-from-2019-to-2023-says-mrfr/523251?utm_source=CURE+Pharmaceutical+Master+Email+List&utm_campaign=019c846a54-Q2_UPDATE_8_7_2019_COPY_01&utm_medium=email&utm_term=0_bf02d4790f-019c846a54-73172501
CURE named “Innovative Business of the Year”
We are happy to announce that the Oxnard Chamber of Commerce presented CURE with the “Innovative Business of the Year” award in April. Mark Udell, CURE’s Chief Accounting Officer, accepted the award on behalf of the company.
Volunteer work with Food Share
We have an ongoing relationship with Ventura County Food Share and this quarter, some of our team members pitched in on work in their garden, weeding the vegetables, planting bok choy and putting down irrigation lines. You too can support Food Share with donations or volunteer work.